Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1996:397:7-13.
doi: 10.1007/978-1-4899-1382-1_2.

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

B Moss  1 , M W Carroll, L S Wyatt, J R Bennink, V M Hirsch, S Goldstein, W R Elkins, T R Fuerst, J D Lifson, M Piatak, N P Restifo, W Overwijk, R Chamberlain, S A Rosenberg, G Sutter
Affiliations
Review

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

B Moss et al. Adv Exp Med Biol. 1996.

Abstract

Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-Fha/np induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA-SIVenv/gag/pol greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-beta gal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.

PubMed Disclaimer

References

    1. Andrew ME, Coupar BEH, Ada GL, Boyle DB. Cell-mediated immune response to influenza virus antigens expressed by vaccinia virus recombinants. Microb Path. 1986;1:443–452. - PubMed
    1. Bennink JR, Yewdell JW, Smith JW, Moller C, Moss B. Recombinant vaccinia virus primes and stimulates influenza virus HA-specific CTL. Nature. 1984;311:578–579. - PubMed
    1. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. 1L-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol. 1995;154:5282–5292. - PMC - PubMed
    1. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol. 1988;62:866–877. - PMC - PubMed
    1. Buller RML, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;317:813–815. - PubMed

MeSH terms

LinkOut - more resources